ARDELYX INC (ARDX)
US0396971071 - Common Stock
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
First Week of May 31st Options Trading For Ardelyx (ARDX)
Ardelyx Enters Oversold Territory (ARDX)
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
ARDX May 10th Options Begin Trading
The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter
Explore why these stocks may explode and could be game-changers in biotechnology, hotels, resorts, cruise lines, and application software.
Ardelyx, Inc. Reports Employment Inducement Grants
Ardelyx, Inc. Reports Employment Inducement Grants
WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Interesting ARDX Put And Call Options For April 26th
The Millionaire’s Watchlist: 3 Stocks Set for a Meteoric Rise
From biotechnology to digital tech endeavors, these stocks offer huge promise for the future, making them stocks to buy now.
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Stocks on the Launchpad: The Next 3 Market Sensations
Navigate the bullish trend in the market by wagering on these three enticing market sensations likely to become multi-bagger investments
Ardelyx GAAP EPS of -$0.12 misses by $0.02, revenue of $34.36M beats by $0.14M (NASDAQ:ARDX)
Ardelyx reports Q4 financial results: GAAP EPS missed by $0.02, while revenue beat estimates.
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue...
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
Pounce on the electric surge of analyst upgrades, guiding you through market uncertainties with considerable aplomb.
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Analyst upgrades consistently offer valuable insights, deftly guiding investors...
3 Revolutionary Biotech Stocks Poised for 10X Surge
Discover three biotech stocks set to soar in a $3.08 trillion market, merging medical innovations with financial growth opportunities.
3 Unstoppable Russell 2000 to Buy in February
These are a few companies that are within the Russell 2000 Index that offer investors great returns and a bright future.
3 Sleeper Stocks Under $15 Ready to Explode by 2029
Discover 3 under-$15 stocks primed for a 2029 explosion, from fintech disruptors to biotech pioneers tackling untreatable rare diseases.
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns
The 3 Best Biotech Stocks to Invest in for Big Gains in 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The quest for prime biotech stocks for gains will always be relevant. Moreover,...
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
Conference call scheduled for 4:30 p.m. Eastern Time